Vir Biotechnology
38 hedge funds and large institutions have $460M invested in Vir Biotechnology in 2019 Q4 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33.36% more ownership
Funds ownership: 0% → 33.36% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB Investment Advisers (UK)
London,
United Kingdom
|
+$303M |
| 2 |
Temasek Holdings
Singapore
|
+$73.7M |
| 3 |
Iconiq Capital
San Francisco,
California
|
+$48M |
| 4 |
Alphabet Inc
Mountain View,
California
|
+$22.3M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$13.2M |
Top Sellers
VIR Hedge Fund Activity: Q4 2019 in Review
38 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2019, worth a combined $460M.
Buyers outnumbered sellers: 38 funds opened new VIR positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SB Investment Advisers (UK), opening a new position worth an estimated $303M.
- 38 institutional investors held Vir Biotechnology (VIR) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $460M of Vir Biotechnology stock for Q4 2019.
- 38 funds opened new Vir Biotechnology positions in Q4 2019 and 0 closed out, a net change of +38 holders.
- The largest Vir Biotechnology buyer in Q4 2019 was SB Investment Advisers (UK), an estimated $303M added.
Based on aggregated 13F filings for Q4 2019.